

## Richard P. Kivel



Rich is a Senior Manager at Bridgewater Associates. Bridgewater is ranked as the largest and best-performing hedge fund manager in the world with over \$120 billion in global investments.

Additionally, Rich serves as Chairman of Rhapsody Biologics, a biotech company focused in the field of vaccine development, with offices in the US and Singapore. Prior to this, Rich served as CEO of TheraGenetics, a UK-based pharmacogenetic diagnostics company. In January 2009, TheraGenetics was acquired by UK based Avacta Group plc. LSE: (AVCT). Rich remained as CEO and continued to lead the growth of TheraGenetics under the new ownership until June 2009.

Rich served as Chairman of the global Board of Directors of the MIT Enterprise Forum and was a member of the MIT Alumni Association Board from 2008-2011. He is a frequent lecturer at MIT as well as a judge for the MIT \$100K Entrepreneurship Competition.

Rich serves as a Board member of both public and private companies in the biotech and high-tech space, such as Rexahn Pharmaceuticals, Inc. (NYSE:RNN), a biopharmaceutical company developing novel cures for cancer and disorders of the central nervous system (CNS).

kivel@mit.edu  
Twitter: kivel1